Oxurion Eyes $12bn Opportunity After Restructuring
New CEO Completes Strategic Review
The Belgium-headquartered group is pulling the plug on its dry AMD research efforts and investments in cancer venture Oncurious to focus on two early-stage compounds that show promise for diabetic macular edema and other retinal diseases.
You may also be interested in...
THR-687’s failure in Phase II marks the second drug to flunk in the disease after a Phase IIa study of THR-317 showed disappointing results in 2019, but THR-149 has shown some encouraging data.
The primary endpoint was missed in a Phase IIa study of Oxurion’s THR-317 in diabetic macular edema, but vision did improve in two patient subgroups.
PTC CEO Stuart Peltz tells Scrip that cost watchdogs are likely to look favorably on the firm’s transformational gene therapy for a distressing rare brain disorder in children who could not even lift their heads before treatment.